Earnings ·
Zimmer Biomet reports Q3 net sales of $2.06B and raises full-year guidance
ZBHZimmer Biomet Holdings, Inc.
On November 4, 2026, Zimmer Biomet Holdings reported third-quarter net sales of $2.063 billion, a 3.1% increase on a reported basis and 3.7% on a constant currency basis compared to the prior year period. Diluted earnings per share were $1.00, down 13.8%, while adjusted diluted EPS was $1.90, consistent with the previous year. The company generated $560 million in operating cash flow and $372.4 million in free cash flow. Zimmer Biomet updated its full-year 2026 financial guidance, raising projected organic constant-currency revenue growth to 3.0%-3.5% from 2.25%-3.25% and adjusted diluted EPS to $8.50-$8.60 from $8.47-$8.59. The company operates in the medical technology industry, manufacturing orthopedic implants, surgical instruments, and digital health solutions.